This article is more than 5 years old. Information may no longer be current.
VIDEO: Expert discusses potential impact of transcatheter mitral valve replacement
Click Here to Manage Email Alerts
CHICAGO — In this video, Joseph Bavaria, MD, cardiac surgeon at the University of Pennsylvania and president of the Society of Thoracic Surgeons, discusses the practice-changing implications of transcatheter mitral valve replacement.
Still in the early feasibility stages in Europe and North America, transcatheter mitral valve replacement has generated “extreme interest,” garnering between $1.2 billion and $1.5 billion in development funding from many different companies, who are experimenting with a variety of patient populations, designs and approaches.
Presently, devices using the transapical approach are large, but are expected to get smaller with further development, Bavaria said.
Additionally, “the transseptal approach is ... very promising,” Bavaria said. “It is probably the preferred approach ... regarding the design of these devices and delivery systems.”
Bavaria said the future of transcatheter mitral valve replacement should be an exciting one, as it may help patients who are unable to benefit from medical therapy, surgery or transcatheter mitral valve repair with the MitraClip device (Abbott Vascular).